Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow patientINFORMation
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Drexel, H.
Right arrow Articles by Saely, C. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Drexel, H.
Right arrow Articles by Saely, C. H.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes Care 28:101-107, 2005
© 2005 by the American Diabetes Association, Inc.


Pathophysiology/Complications
Original Article

Is Atherosclerosis in Diabetes and Impaired Fasting Glucose Driven by Elevated LDL Cholesterol or by Decreased HDL Cholesterol?

Heinz Drexel, MD1,2, Stefan Aczel, MD1,2, Thomas Marte, MD1, Werner Benzer, MD2, Peter Langer, PHD1, Willi Moll, MD3 and Christoph H. Saely, MD1,2

1 Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria
2 Department of Medicine, Academic Teaching Hospital Feldkirch, Feldkirch, Austria
3 Institute for Clinical Chemistry, Feldkirch, Austria

Address correspondence and reprint requests to Heinz Drexel, MD, Professor of Medicine, VIVIT, Carinagasse 47, A-6800 Feldkirch, Austria. E-mail: vivit{at}lkhf.at

OBJECTIVE—To evaluate the atherogenicity of lipids in coronary patients with normal fasting glucose (NFG), impaired fasting glucose (IFG), and type 2 diabetes.

RESEARCH DESIGN AND METHODS—Serum lipid values, the presence of angiographic coronary artery disease (CAD) at baseline, and the incidence of vascular events over 2.3 years were recorded in 750 consecutive patients undergoing coronary angiography.

RESULTS—Triglycerides significantly (P < 0.001) increased and HDL cholesterol (P < 0.001) as well as LDL particle diameter (P < 0.001) significantly decreased from subjects with NFG <5.6 mmol/l (n = 272) over patients with IFG ≥5.6 mmol/l (n = 314) to patients with type 2 diabetes (n = 164). Factor analysis revealed two factors in the lipid profiles of our patients: triglycerides, HDL cholesterol, apolipoprotein A1, and LDL particle diameter loaded high on an HDL-related factor, and total cholesterol, LDL cholesterol, and apolipoprotein B loaded high on an LDL-related factor. In patients with type 2 diabetes, the HDL-related factor (odds ratio 0.648 [95% CI 0.464–0.904]; P = 0.011), but not the LDL-related factor (0.921 [0.677–1.251]; P = 0.597), was associated with significant coronary stenoses ≥50%. Consistently, in the prospective study, the HDL-related factor (0.708 [0.506–0.990]; P = 0.044), but not the LDL-related factor (1.362 [0.985–1.883]; P = 0.061), proved significantly predictive for vascular events in patients with type 2 diabetes.

CONCLUSIONS—The low HDL cholesterol/high triglyceride pattern is associated with the degree of hyperglycemia. In coronary patients with type 2 diabetes, this pattern correlates with the prevalence of CAD and significantly predicts the incidence of vascular events.

Abbreviations: CAD, coronary artery disease • IFG, impaired fasting glucose • NFG, normal fasting glucose


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Find additional patient-related information at:

Atherosclerosis, Cholesterol, and Diabetes


This article has been cited by other articles:


Home page
Diabetes CareHome page
R. W. Grant and J. B. Meigs
Prevalence and Treatment of Low HDL Cholesterol Among Primary Care Patients With Type 2 Diabetes: An unmet challenge for cardiovascular risk reduction
Diabetes Care, March 1, 2007; 30(3): 479 - 484.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
T. R. Pedersen
The gap between theory and practice: what do the trials tell us?
Eur. Heart J. Suppl., October 1, 2006; 8(suppl_F): F10 - F16.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
E. Bruckert
Epidemiology of low HDL-cholesterol: results of studies and surveys
Eur. Heart J. Suppl., October 1, 2006; 8(suppl_F): F17 - F22.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
H. Drexel
Reducing risk by raising HDL-cholesterol: the evidence
Eur. Heart J. Suppl., October 1, 2006; 8(suppl_F): F23 - F29.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
C. H. Saely, L. Koch, F. Schmid, T. Marte, S. Aczel, P. Langer, G. Hoefle, and H. Drexel
Adult Treatment Panel III 2001 but Not International Diabetes Federation 2005 Criteria of the Metabolic Syndrome Predict Clinical Cardiovascular Events in Subjects Who Underwent Coronary Angiography
Diabetes Care, April 1, 2006; 29(4): 901 - 907.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. H. Saely, S. Aczel, T. Marte, P. Langer, G. Hoefle, and H. Drexel
The Metabolic Syndrome, Insulin Resistance, and Cardiovascular Risk in Diabetic and Nondiabetic Patients
J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5698 - 5703.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
M. B. Schulze and K. Hoffmann
Is Atherosclerosis in Diabetes and Impaired Fasting Glucose Driven by Elevated LDL Cholesterol or by Decreased HDL Cholesterol?: Response to Drexel et al.
Diabetes Care, May 1, 2005; 28(5): 1264 - 1264.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2005 by the American Diabetes Association.